2 results
Approved WMOCompleted
Primary Objective:Assess the safety and explore the biologically effective dose (BED) and/or the maximum tolerated dose (MTD) and/or the recommended Phase II dose (RP2D) of AZD4573 in patients with relapsed or refractory haematological…
Approved WMOWill not start
Primary - To evaluate the efficacy of parsaclisib in the treatment of participants with wAIHA.Secondary - To further evaluate the efficacy of parsaclisib in the treatment of participants with wAIHA.